Kardigan, Inc. Common Stock (KARD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kardigan, Inc. Common Stock (KARD) has a cash flow conversion efficiency ratio of -0.082x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-50.55 Million) by net assets ($615.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KARD stock market capitalisation for the company's overall valuation and market capitalisation.
Kardigan, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Kardigan, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kardigan, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kardigan, Inc. Common Stock ranked by their cash flow conversion efficiency. See Kardigan, Inc. Common Stock debt service capacity to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Integral Ad Science Holding LLC
NASDAQ:IAS
|
0.044x |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
-0.016x |
|
Tri Continental Closed Fund
NYSE:TY
|
-0.167x |
|
H2O America
NASDAQ:HTO
|
0.051x |
|
China Nonferrous Metal Industry’s Foreign Engineering and Construction Co Ltd
SHE:000758
|
-0.124x |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
-0.116x |
|
Shanghai Jahwa United Co Ltd
SHG:600315
|
0.020x |
|
SRH Total Return Fund Inc.
NYSE:STEW
|
0.015x |
Annual Cash Flow Conversion Efficiency for Kardigan, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Kardigan, Inc. Common Stock from 2024 to 2025. View latest Kardigan, Inc. Common Stock stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-250.34 Million | $-151.06 Million | 0.603x | +166.67% |
| 2024-12-31 | $-83.19 Million | $-18.82 Million | 0.226x | -- |
About Kardigan, Inc. Common Stock
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI… Read more